Aeglea BioTherapeutics Announces Leadership Change
July 20 2017 - 4:01PM
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company
committed to developing enzyme-based therapeutics in the field of
amino acid metabolism to treat rare genetic diseases and cancer,
today announced that David G. Lowe, Ph.D., resigned as the
company’s president, chief executive officer and director,
effective immediately. Anthony Quinn, M.B Ch.B, Ph.D., has been
appointed to serve as interim chief executive officer while the
company conducts a comprehensive search for a permanent chief
executive officer.
Dr. Quinn has played a significant role in the leadership of
Aeglea. He has been a member of the board of directors since 2016
and recently served as interim chief medical officer. With more
than 20 years’ experience in the pharmaceutical and biotech
industries, Dr. Quinn has an accomplished track record as a drug
developer. He served as head of R&D and chief medical officer
at Synageva BioPharma Corp. until the company’s acquisition by
Alexion Pharmaceuticals in 2015. During his tenure at Synageva, he
played a key role in securing European and U.S. approvals of
Kanuma™ for Lysosomal Acid Lipase Deficiency and in building the
company’s research and development organization and rare disease
drug pipeline. Prior to Synageva, he was head of clinical research
and exploratory development at Roche, which included leadership
responsibility for the inflammation disease portfolio including the
MabtheraTM, RituxanTM and ActemraTM programs.
“In addition to his seasoned leadership, Anthony brings broad
experience in drug development, particularly in rare genetic
disease. This will be critical to Aeglea’s future success as we
continue to advance our preclinical and clinical pipeline,” said
Armen Shanafelt, Ph.D., chairman of Aeglea’s board of directors.
“With our strong management team, we are confident Anthony will
provide continuity of leadership while we undergo a search for a
permanent CEO.”
Dr. Shanafelt added, “It has been a privilege to work with David
and I’d like to thank him for all that he has accomplished with
Aeglea over the last several years through his hard work and
passion for the company. We wish him well on the next phase of his
career.”
Under Dr. Lowe’s leadership, Aeglea progressed from a
preclinical-stage to a clinical-stage company, with three ongoing
clinical trials in rare genetic disease and cancer. He played a key
role in securing institutional financing for Aeglea, including a
successful initial public offering in 2016.
“It has been an honor to work with the team at Aeglea,” said Dr.
Lowe. “I am proud that we have established such a strong foundation
to further Aeglea’s mission of providing new therapies that address
unmet needs in rare genetic diseases and cancer.”
About Aeglea BioTherapeutics Aeglea is a
biotechnology company committed to developing enzyme-based
therapeutics in the field of amino acid metabolism to treat rare
genetic diseases and cancer. The company’s engineered human enzymes
are designed to modulate the extremes of amino acid metabolism in
the blood to reduce toxic levels of amino acids in inborn errors of
metabolism or target tumor metabolism for cancer treatment.
AEB1102, Aeglea’s lead product candidate, is currently being
studied in two ongoing Phase 1 clinical trials in patients with
advanced solid tumors and acute myeloid leukemia/myelodysplastic
syndrome (AML/MDS). Additionally, Aeglea is recruiting patients
into its ongoing Phase 1/2 trial of AEB1102 for the treatment of
patients with Arginase 1 Deficiency. The company is building a
pipeline of additional product candidates targeting key amino
acids, including AEB4104, which degrades homocystine, a target for
an inborn error of metabolism, as well as two potential treatments
for cancer, AEB3103, which degrades cysteine/cystine, and AEB2109,
which degrades methionine. For more information, please
visit http://aegleabio.com.
Safe Harbor / Forward Looking StatementsThis
press release contains “forward-looking” statements within the
meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by words such as: “anticipate,”
“intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,”
“expect,” “strategy,” “future,” “likely,” “may,” “should,” “will”
and similar references to future periods. These statements are
subject to numerous risks and uncertainties that could cause actual
results to differ materially from what we expect. Examples of
forward-looking statements include, among others, the potential
therapeutic benefits and economic value of our product candidates.
Further information on potential risk factors that could affect our
business and its financial results are detailed in our most recent
Quarterly Report on Form 10-Q for the quarter ended March 31, 2017,
filed with the Securities and Exchange Commission (SEC), and other
reports as filed with the SEC. We undertake no obligation to
publicly update any forward-looking statement, whether written or
oral, that may be made from time to time, whether as a result of
new information, future developments or otherwise.
Media Contact:
Kelly Boothe, Ph.D.
Pure Communications
415.946.1076
media@aegleabio.com
Investor Contact:
Charles N. York II
Chief Financial Officer
Aeglea BioTherapeutics
investors@aegleabio.com
Aeglea BioTherapeutics (NASDAQ:AGLE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aeglea BioTherapeutics (NASDAQ:AGLE)
Historical Stock Chart
From Apr 2023 to Apr 2024